eli lilly glp-1 agonist Orforglipron: Lilly's New Oral Weight-loss Pill Eli Lilly Stock Up on

SWOT Analysis 5

In a population without specific risk factors for thyroid cancer, the benefits of GLP-1 RAs will largely outweigh the harm. The European Medicines Agency in October 2023 announced that they did not find a causal link between GLP-1s and thyroid cancer after a months-long review

44,45 Using the FDA Sentinel System, Maro et al found that the incidence of NAION was not increased within 6 months of semaglutide initiation

Clinical trials show slightly greater average weight loss with tirzepatide, and individuals with genetic predispositions toward GIP-pathway activation often respond more robustly

doi: 10.1210/en.2003-0143

Endocr Connect (2017) 6(8):85665